Pharm Friday August 1, 2008
August 1, 2008 by Becky Ramsey
Filed under Business
New Alzheimer’s Drug Discouraging but Moving Forward
Elan will go ahead with larger trials of its Alzheimer’s drug, bapineuzumab, despite disappointing results in smaller trials, little fanfare, and falling company stocks. A desperate need for Alzheimer’s treatments drives the drug forward, albeit with little hope.
FDA Orders a Prescription Label Change
For the first time since a 2007 law that allows the FDA to order a prescription label to be changed was put into place, the agency has told biotech. company, Amgen, to change labels on drugs used to treat chemotherapy-induced anemia to indicate the possibility of the drugs iworsening the effects of the cancer.
FDA Regulates Tobacco
Read Jen’s post about this monumental move.
Stavzor Receives FDA Approval
Noven Pharmaceuticals has received FDA approval for its drug, Stavzor, indicated to treat manic episodes related to bipolar disorder, seizures, and migraines.
UCB Drug Not Approved for Diabetes Neuropathic Pain
UCB received a letter from the FDA stating that its drug, lacosamide (Vimpat), has not been approved for the treatment of diabetic neuropathic pain.
A busy week for the FDA! What pharm. news did you read/hear this week?
